Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
RESEARCH TOOLSreports
CG Oncology, Inc. (CGON) Stock Price & Analysis
52 Followers
CGON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.77 - $50.23
Previous Close$27.32
Volume25.20K
Average Volume (3M)633.36K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Beta1.93
Next Earnings
May 09, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume633,357
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$68.20Price Target Upside146.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
CG Oncology, Inc. News
Bulls Say, Bears Say
Bulls Say
Analyst UpgradeCGON receives an upgrade to Buy from Neutral, indicating a positive shift in market sentiment based on promising clinical data.
Market OpportunityWith a market size estimated at $2.5B for cretostimogene, a substantial commercial opportunity presents itself for investors.
Safety And EfficacyCretostimogene's safety profile and durable efficacy garner physician preference, potentially increasing its adoption in NMIBC treatment.
Bears Say
Clinical TrialsThe differentiation of cretostimogene's complete response rate when compared to TAR-200 is still under debate.
Financial HealthAnnualized Cash Burn is $107.0 million, which may raise concerns about the company's financial sustainability over time.
Safety Profile63% of patients experienced a treatment related adverse event.
---
Ownership Overview
15.78% Insiders
2.75% Mutual Funds
23.87% Other Institutional Investors
57.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $25.77 and its highest was $50.23 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
Currently, no data Available
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is May 09, 2024 which is 6 days ago.
How were CG Oncology, Inc.’s earnings last quarter?
Currently, no data Available
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -$0.31.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 66,640,150 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
---
CG Oncology, Inc. Stock Smart Score
CGON Stock 12 Month Forecast
Average Price Target
$68.20
▲(146.30% Upside)
Technical Analysis
Best Analysts Covering CGON
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-31.70%
assigned a buy rating 7 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -31.70% per trade.
---